Radiation-induced prodrug activation: extending combined modality therapy for some solid tumours

Area of Science:

• Oncology
• Radiotherapy
• Medicinal Chemistry

Background:

• Combined chemoradiotherapy is standard for locally advanced solid tumors.
• Systemic toxicity often limits chemotherapy delivery.
• Novel strategies are needed to reduce toxicity and enhance efficacy.

Purpose of the Study:

• To investigate radiation-induced prodrug activation using organic azides.
• To evaluate the efficacy and systemic toxicity of this approach in preclinical models.
• To explore its potential application in chemoradiation and targeted drug delivery.

Main Methods:

• Utilized organic azides activated by radiotherapy under hypoxic conditions.
• Tested uncaging of pazopanib and doxorubicin in preclinical tumor models.
• Assessed anticancer efficacy and systemic toxicity compared to conventional drug administration.

Main Results:

• Organic azides were successfully reduced and activated by radiotherapy.
• Activated prodrugs showed efficacy comparable to parent drugs.
• Systemic toxicity was significantly lower than with conventional chemotherapy.

Conclusions:

• Radiation-induced prodrug activation is a viable strategy to reduce systemic toxicity in cancer therapy.
• This approach holds potential for treating glioblastoma and other solid tumors.
• Further preclinical validation is warranted, focusing on drug activation confirmation and optimal timing.